Quarterly report pursuant to Section 13 or 15(d)

Underwritten Offering Common Stock and At-the-Market Offering Program (Details)

v3.5.0.2
Underwritten Offering Common Stock and At-the-Market Offering Program (Details)
$ / shares in Units, $ in Thousands
 2 Months Ended 3 Months Ended 12 Months Ended
Apr. 22, 2016
USD ($)
shares
Apr. 19, 2016
$ / shares
shares
Aug. 28, 2015
USD ($)
Jun. 30, 2016
shares
Jun. 30, 2016
USD ($)
shares
Mar. 31, 2016
USD ($)
shares
Number of common stock shares available in public offering   2,700,000        
Beneficial ownership of common stock resulting from purchase of stock in public offering (as a percent)   4.99        
Number of warrants or shares of common stock to be sold to purchase common stock   2        
Net proceeds from sale of the common stock, after deducting fees and other offering expenses (in dollars) | $ $ 13,100       $ 13,128 $ 12,700
Common stock sold (in shares)           6,900,000
Maximum            
Aggregate offering price for at-the-market offering program | $     $ 30,000      
Series A Warrants            
Number of shares of common stock that could be purchased with warrants   4,100,000        
Number of warrants or shares of common stock to be sold to purchase common stock   1        
Number of shares of common stock purchased with each warrant   1        
Exercise price (in dollars per share) | $ / shares   $ 3.50        
Length of time from issue date until warrants are exercisable   6 months        
Length of time from exercise date until warrants expire   5 years        
Balance, April 22, 2016 (in shares)       4,107,500    
Balance, end of period (in shares) 4,107,500     4,107,500 4,107,500  
Series B Warrants            
Number of warrants or shares of common stock to be sold to purchase common stock   2        
Exercise price (in dollars per share) | $ / shares   $ 3.48        
Length of time from exercise date until warrants expire   9 months        
Balance, April 22, 2016 (in shares)       5,515,000    
Warrants exercised (in shares)       (3,628,750)    
Balance, end of period (in shares) 5,515,000     1,886,250 1,886,250  
Series B Warrants | Maximum            
Number of shares of common stock that could be purchased with warrants   5,500,000